Cisplatin and 5-fluorouracil with or without epidermal growth factor receptor inhibition panitumumab for patients with non-resectable, advanced or metastatic oesophageal squamous cell cancer: a prospective, open-label, randomised phase III AIO/EORTC trial (POWER)

Cisplatin and 5-fluorouracil with or without epidermal growth factor receptor inhibition panitumumab for patients with non-resectable, advanced or metastatic oesophageal squamous cell cancer: a prospective, open-label, randomised phase III AIO/EORTC trial (POWER)

•CF is the best palliative regimen in adv. ESCC.•Panitumumab added to CF failed to improve survival.•Low sEGFR linked to better PFS. BackgroundPalliative chemotherapy of advanced oesophageal squamous cell cancer (ESCC) consists of cisplatin/5-fluorouracil (CF) to target epidermal growth factor recep...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριοι συγγραφείς: Markus Moehler, Annett Maderer, Peter Thuss‐Patience, Baruch Brenner, Jens Meiler, Thomas Jens Ettrich, Ralf‐Dieter Hofheinz, S. Al-Batran, Arndt Vogel, Lothar Mueller, Manfred P. Lutz, Florian Lordick, María Alsina, K Borchert, Richard Greil, Wolfgang Eisterer, Arno Schad, Julia Slotta‐Huspenina, Eric Van Cutsem, Sylvie Lorenzen
Μορφή: Artigo
Γλώσσα:Αγγλικά
Έκδοση: 2020
Διαθέσιμο Online:https://doi.org/10.1016/j.annonc.2019.10.018
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Διαδίκτυο

https://doi.org/10.1016/j.annonc.2019.10.018

Παρόμοια τεκμήρια